Comparison of Line Probe Assay (LPA) and Mycobacterium Growth Indicator Tubes (MGIT) Assay for Second-line TB Drug Susceptibility Testing

Towifah Fauziah Choerunisa, Leni Lismayanti, Tiene Rostini, Ryan Bayusantika, Ida Parwati


BACKGROUND: Tuberculosis (TB) infection is one of the most prominent health issues in the world, including in Indonesia. TB is evolving into multidrug-resistant tuberculosis (MDR-TB) and requiring second-line TB drugs. Mycobacterium growth indicator tube (MGIT) is the gold standard for susceptibility testing of second-line TB drugs. Alternatively, line probe assay (LPA), which detects genes resistant to second-line TB drugs, takes a shorter time to run. This study aims to compare MGIT and LPA's ability to detect TB resistance to second-line TB drugs and observe mutation patterns of genes encoding second-line TB drugs.

METHODS: This was an observational analytic study, using cross-sectional method. The data were acquired from the MDR-TB clinic’s medical records at the Dr. Hasan Sadikin Hospital from September to December 2019. LPA and MGIT test were conducted at the Health Laboratory Hall of West Java Province, then tested using Kolmogorov-Smirnov and chi-square statistic.

RESULTS: From 121 subjects, 113 people were not resistant to the second-line TB drugs, which was examined using both LPA and MGIT (93.4%), p=0.991. Mutations were found in gyrA and rrs gene. There was no significant difference between the proportion of subjects resistant to the second-line of TB drugs tested using LPA and MGIT.

CONCLUSION: LPA is an alternative method to MGIT because it requires a shorter time and reduces the risk of exposure that will improve MDR-TB patients management.

KEYWORDS: line probe assay (LPA), multidrug-resistant TB, mycobacterium growth indicator tube (MGIT), second-line TB drugs


Full Text:



Floyd K, Anderson L, Baddeley A, Baena IG, Gebreselassie N, Gilpin C, et al. Global Tuberculosis Report. Geneva: WHO; 2018, article.

Lima SSS, Clemente WT, Palaci M, Rosa RV, Antunes CM de F, Serufo JC. Conventional and molecular techniques in the diagnosis of pulmonary tuberculosis: a comparative study. J Bras Pneumol. 2010; 34: 1056-62, CrossRef.

Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, et al. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci. 2013; 345: 143-8, CrossRef.

Hain Lifescience. Genotype MTBDRplus VER 2.0: Molecular Genetic Assay for Identification of the M. tuberculosis Complex and its Resistance to Rifampicin and Isoniazid from Clinical Specimens and Cultivated Samples. Nehren: Hain Lifescience GmbH; 2012, article.

Metchock B. New TB Diagnostic Tools and the Challenges of Interpreting Discordant Results. Atlanta: Souteatern Natl TB Center, CDC; 2012, article.

GLI. Line Probe Assays for Drug-resistant Tuberculosis Detection Interpretation and Reporting Guide for Laboratory Staff and Clinicians. [n.p.]: Global Laboratory Iniative; 2018, article.

GLI. Mycobacteriology Laboratory Manual. [n.p.]: Global Laboratory Iniative; 2014, article.

Gardee Y, Dreyer AW, Koornhof HJ, Omar SV, Silva P, Bhyat Z. Evaluation of the genotype MTBDR sl tuberculosis isolates in South Africa. J Clin Microbiol. 2017; 55: 791-800, CrossRef.

Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis : an update. Arch Toxicol. 2016; 90: 1585-604, CrossRef.

Kemenkes RI. Petunjuk Teknis Pengobatan Pasien TB Resistan Obat dengan Panduan Standar Jangka Pendek di Fasyankes TB Resistan Obat. Jakarta: Kemenkes RI; 2017, article.

Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infect Dis. 2017; 17: 1-8, CrossRef.

Hain-Lifescience. GenoType MTBDRsl VER 2.0 - Instructions for use. IFU-317A-01. Nehren: Hain Lifescience GmbH; 2015, article.

Parwati I, Van Crevel R, Sudiro M, Alisjahbana B, Pakasi T, Kremer K, et al. Mycobacterium tuberculosis population structures differ significantly on two Indonesian islands. J Clin Microbiol. 2008; 46: 3639-45, CrossRef.

Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Zanden AGM, et al. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis. 2010; 201: 553-7, CrossRef.

Couvin D, Reynaud Y, Rastogi N. Two tales: Worldwide distribution of Central Asian (CAS) versus ancestral East-African Indian (EAI) lineages of Mycobacterium tuberculosis underlines a remarkable cleavage for phylogeographical, epidemiological and demographical characteristics. PLoS ONE 14(7): e0219706, CrossRef.

Chien J, Chiu W, Chien S, Chiang C, Yu C, Hsueh P. Mutations in gyrA and gyrB among fluoroquinolone- and multidrug- resistant mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2016; 60: 2090-6, CrossRef.

Ali A, Hasan R, Jabeen K, Jabeen N, Qadeer E, Hasan Z. Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. Antimicrob Agents Chemother. 2011; 55: 5654-9, CrossRef.

Weber W. Silent Mutation. Oxford: Oxford Univ Press USA; 2008.

Cui Z, Wang J, Lu J, Huang X, Hu Z. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis. 2011; 11: 78, CrossRef.

Ndjeka N, Richard P, Farley J, Lowensen K, Mlandu N, Nyakinye K, et al. Multidrug-Resistant Tuberculosis National Clinical Management Training. Singapore: Pyrobett; 2017.

Syafira SZ, Zavitri NG, Yan S, Sribudiani Y, Lezhava A, Chaidir L. Positivity rate of pyrosequencing to diagnose drug-resistant tuberculosis directly from sputum with different bacterial load. Indones Biomed J. 2020; 12: 313-9, CrossRef.


Indexed by:






The Prodia Education and Research Institute